Bcl-2 overexpression leads to increases in suppressor of cytokine signaling-3 expression in B cells and De novo follicular lymphoma

Molecular Cancer Research

Volumn 2, Issue 11, 2004, Pages 620-631

  Vanasse, Gary J ^a   Winn, Robert K ^b   Rodov, Sofya ^a   Zieske, Arthur W ^a   Li, John T ^b   Tupper, Joan C ^b   Tang, Jingjing ^b   Raines, Elaine W ^b   Peters, Mette A ^c   Yeung, Ka Yee ^c   Harlan, John M ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD19 ANTIGEN; OLIGONUCLEOTIDE; PROTEIN; STAT3 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 3; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; B CELL LEUKEMIA; B LYMPHOCYTE; COHORT ANALYSIS; CONTROLLED STUDY; DNA MICROARRAY; FOLLICULAR LYMPHOMA; GENE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE INDUCTION; GENE LOCATION; GENE OVEREXPRESSION; GENE REPRESSION; GENETIC DAMAGE; GENETIC MARKER; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERPLASIA; IMMUNOHISTOCHEMISTRY; MALIGNANT TRANSFORMATION; MOUSE; MOUSE STRAIN; NONHUMAN; NUCLEOTIDE SEQUENCE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTO ONCOGENE; SIGNAL TRANSDUCTION; SOCS3 GENE; TISSUE SECTION; TONSIL; TRANSGENIC MOUSE; UNINDEXED SEQUENCE;

ANIMALS; B-LYMPHOCYTES; CELL LINE; DNA-BINDING PROTEINS; DOWN-REGULATION; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; LYMPHOMA, FOLLICULAR; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; REPRESSOR PROTEINS; STAT3 TRANSCRIPTION FACTOR; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS; TONSIL; TRANS-ACTIVATION (GENETICS); TRANS-ACTIVATORS; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

ANIMALIA; DROMAIUS NOVAEHOLLANDIAE; MUS MUSCULUS;

EID: 9344270512     PISSN: 15417786     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (60)

1. Harris N, Jaffe E, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994;84:1361-92.
2. Horning SJ. Natural history of and therapy for the indolent non-Hodgkin's lymphomas. Semin Oncol 1993;20:75-88.
3. Ersboll J, Schultz HB, Pedersen-Bjergaard J, Nissen NI. Follicular low-grade non-Hodgkin's lymphoma: long term outcome with or without tumor progression. Eur J Haematol 1989;42:155-63.
4. Finger LR, Harvey RC, Moore RCA, Showe LC, Croce CM. A common mechanism of chromosomal translocation in T- and B-cell neoplasia. Science 1986;234:982-5.
5. H on chromosome 14 and near a transcriptional unit on 18. Cell 1985;41:899-906.
6. Cleary ML, Sklar J. Nucleotide sequence of a t(14;18) chromosomal breakpoint in follicular lymphoma and demonstration of a breakpoint cluster region near a transcriptionally active locus on chromosome 18. Proc Natl Acad Sci U S A 1985;82:7439-43.
7. Tsujimoto Y, Gorham J, Cossman J, Jaffe E, Croce CM. The t(14;18) chromosome translocations involved in B-cell neoplasms result from mistakes in VDJ joining. Science 1985;22:1390-3.
8. Yang E, Korsmeyer SJ. Molecular thanatopsis: a discourse on the BCL2 family and cell death. Blood 1996;88:386-401.
9. Vaux DL, Cory S, Adams JM. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 1988;335:440-2.
10. McDonnell TJ, Deane N, Platt FM, et al. Bcl-2-immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation. Cell 1989;57:79-88.
11. McDonnell TJ, Korsmeyer SJ. Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice transgenic for the t(14:18). Nature 1991;349:254-6.
12. Strasser A, Harris AW, Cory S. Eμ-bcl-2 transgene facilitates spontaneous transformation of early pre-B and immunoglobulin secreting cells but not T cells. Oncogene 1993;8:1-9.
13. Strasser A, Harris AW, Bath ML, Cory S. Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and Bcl-2. Nature 1990;348:331-3.
14. Limpens J, Stad R, Vos C, et al. Lymphoma-associated translocation t(14;18) in blood B cells of normal individuals. Blood 1995;85:2528-36.
15. Paltiel O, Zelenets A, Sverdlin I, Gordon L, Ben-Yehuda D. Translocation t(14;18) in healthy individuals: preliminary study of its association with family history and agricultural exposure. Ann Oncol 2000;11:78-80.
16. Aster J, Kobayashi Y, Shiota M, Mori S, Sklar J. Detection of the t(14;18) at similar frequencies in hyperplastic lymphoid tissues from American and Japanese patients. Am J Pathol 1992;141:291-9.
17. Liu Y, Hernandez A, Shibata D, Cortopassi G. Bcl2 translocation frequency rises with age in humans. Proc Natl Acad Sci U S A 1994;91:8910-4.
18. Lancry L, Roulland S, Roue G, et al. No BCL-2 protein over expression but BCL-2/IgH rearrangements in B cells of patients with persistent polyclonal B-cell lymphocytosis. Hematol J 2001;2:228-33.
19. Lestou VS, Gascoyne RD, Sehn L, et al. Muticolour fluorescence in situ hybridization analysis of t(14;18)-positive follicular lymphoma and correlation with gene expression data and clinical outcome. Br J Haematol 2003;122:745-59.
20. Alizadeh AA, Eisen MB, Davis ER, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2003;403:503-11.
21. Shipp MA, Ross KN, Tamayo P, et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 2002;8:68-74.
22. Huang JZ, Sanger WG, Greiner TC, et al. The t(14;18) defines a unique subset of diffuse large B-cell lymphoma with a germinal center B-cell gene expression profile. Blood 2002;1:2285-90.
23. Husson H, Carideo EG, Neuberg D, et al. Gene expression profiling of follicular lymphoma and normal germinal center B cells using cDNA arrays. Blood 2002;99:282-9.
24. Robetorye RS, Bohling SD, Morgan JW, Fillmore GC, Lim MS, Elenitoba-Johnson KS. Microarray analysis of B-cell lymphoma cell lines with the t(14;18). J Mol Diagn 2002;4:123-36.
25. Bohen SP, Troyanskaya OG, Alter O, et al. Variation in gene expression patterns in follicular lymphoma and the response to rituximab. Proc Natl Acad Sci 2003;100:1926-30.
26. de Vos S, Hofmann WK, Grogan TM, et al. Gene expression profile of serial samples of transformed B-cell lymphomas. Lab Invest 2003;83:271-85.
27. Lossos IS, Alizadeh AA, Diehn M, et al. Transformation of follicular lymphoma to diffuse large-cell lymphoma: alternative patterns with increased or decreased expression of c-myc and its regulated genes. Proc Natl Acad Sci U S A 2002;99:8886-91.
28. Strasser A, Whittingham S, Vaux DL, et al. Enforced BCL2 expression in B-lymphoid cells prolongs antibody responses and elicits autoimmune disease. Immunology 1991;88:8661-5.
29. Strasser A, Harris AW, Corcoran LM, Cory S. Bcl-2 expression promotes B- but not T-lymphoid development in scid mice. Nature 1994;368:457-60.
30. Starr R, Willson TA, Viney EM, et al. A family of cytokine-inducible inhibitors of signalling. Nature 1997;387:917-21.
31. Naka T, Narazaki M, Hirata M, et al. Structure and function of a new STAT-induced STAT inhibitor. Nature 1997;387:924-9.
32. Endo TA, Masuhara M, Yokouchi M, et al. A new protein containing an SH2 domain that inhibits JAK kinases. Nature 1997;387:921-4.
33. Alexander WS, Hilton DJ. The role of cytokine signaling (SOCS) proteins in regulation of the immune response. Annu Rev Immunol 2004;22:503-29.
34. Hilton DJ, Richardson RT, Alexander WS, et al. Twenty proteins containing a C-terminal SOCS box form five structural classes. Proc Natl Acad Sci U S A 1998;95:114-9.
35. Davey HW, McLachlan MJ, Wilkins RJ, Hilton DJ, Adams TE. STAT5b mediates the GH-induced expression of SOCS-2 and SOCS-3 mRNA in the liver. Mol Cell Endocrinol 1999;158:111-6.
36. Auernhammer CJ, Bousquet C, Melmed S. Autoregulation of pituitary corticotroph SOCS-3 expression: characterization of the murine SOCS-3 promoter. Proc Natl Acad Sci U S A 1999;96:6964-9.
37. Emanuelli B, Peraldi P, Filloux C, et al. SOCS-3 is an insulin-induced negative regulator of insulin signaling. J Biol Chem 2000;275:15985-91.
38. He B, You L, Uematsu K, et al. Cloning and characterization of a functional promoter of the human SOCS-3 gene. Biochem Biophys Res Commun 2003;301:386-91.
39. O'Shea JJ, Gadina M, Schreiber RD. Cytokine signaling in 2002: new surprises in the JAK/STAT pathway. Cell 2002;109:5121-31.
40. Yasukawa H, Misawa H, Sakamoto H, et al. The JAK-binding protein JAB inhibits JAK tyrosine kinase activity through binding in the activation loop. EMBO J 1999;18:1309-20.
41. Sasaki A, Yasukawa H, Shouda T, Kitamura T, Dikic I, Yoshimura A. CIS3/ SOCS-3 suppresses erythropoietin (EPO) signaling by binding the EPO receptor and JAK2. J Biol Chem 2000;275:29338-47.
42. Nicholson SE, De Souza D, Fabri LJ, et al. Suppressor of cytokine signaling-3 preferentially binds to the SHP-2 binding site on the shared cytokine receptor subunit gp130. Proc Natl Acad Sci USA 2000;97:6493-8.
43. Lehmann U, Schmitz J, Weissenbach M, et al. SHP2 and SOCS3 contribute to tyr-759-dependent attenuation of interleukin-6 signaling through gp130. J Biol Chem 2003;278:661-71.
44. Egwuagu CE, Yu C-R, Zhang M, Mahdi RM, Kim SJ, Gery I. Suppressors of cytokine signaling proteins are differentially expressed in TH1 and TH2 cells: implications for TH cell lineage commitment and maintenance. J Immunol 2002;168:3181-7.
45. Cohney SJ, Sanden D, Cacalano NA, et al. SOCS-3 is tyrosine phosphorylated in response to interleukin-2 and suppresses STAT5 phosphorylation and lymphocyte proliferation. Mol Cell Biol 1999;19:4980-8.
46. Banerjee A, Banks AS, Nawijn MC, Chen XP, Rothman PB. Cutting edge: suppressor of cytokine signaling 3 inhibits activation of NFATp. J Immunol 2002;168:4277-81.
47. Seki Y, Inoue H, Nagata N, et al. SOCS-3 regulates onset and maintenance of TH2-mediated allergic responses. Nat Med 2003;9:1047-54.
48. Lang R, Pauleau A-L, Parganas E, et al. SOCS3 regulates the plasticity of gp130 signaling. Nat Immunol 2003;4:546-50.
49. Croker BA, Krebs DL, Zhang J-G, et al. SOCS3 negatively regulates IL-6 signaling in vivo. Nat Immunol 2003;4:540-5.
50. Yasukawa H, Ohishi M, Mon H, et al. IL-6 induces an anti-inflammatory response in the absence of SOCS3 in macrophages. Nat Immunol 2003;4:551-6.
51. Croker BA, Metcalf D, Robb L, et al. SOCS3 is a critical physiological negative regulator of G-CSF signaling and emergency granulopoiesis. Immunity 2004;20:153-65.
52. Sakai I, Takeuchi K, Yamauchi H, Narumi H, Fujita S. Constitutive expression of SOCS3 confers resistance to IFN-α in chronic myelogenous leukemia cells. Blood 2002;100:2926-31.
53. Brender C, Nielsen M, Kaltoft K, et al. STAT3-mediated constitutive expression of SOCS-3 in cutaneous T-cell lymphoma. Blood 2001;97:1056-62.
54. Schuringa JJ, Wierenga AT, Kruijer W, Vellenga E. Constitutive stat3, tyr705, and ser727 phosphorylation in acute myeloid leukemia cells caused by the autocrine secretion of interleukin-6. Blood 2000;95:3765-70.
55. Brocke-Heidrich K, Kretzschmar AK, Pfeifer G, et al. Interleukin-6- dependent gene expression profiles in multiple myeloma INA-6 cells reveal a Bcl-2 family-independent survival pathway closely associated with Stat3 activation. Blood 2004;103:242-51.
56. Hughes TR, Roberts CJ, Dai H, et al. Widespread aneuploidy revealed by DNA microarray expression profiling. Nat Genet 2000;25:333-7.
57. Schadt EE, Monks SA, Drake TA, et al. Genetics of gene expression surveyed in maize, mouse and man. Nature 2003;422:297-302.
58. Drachman JG, Griffin JD, Kaushansky K. The c-mpl ligand (thrombopoietin) stimulates tyrosine phosphorylation of JAK2, Shc, and c-mpl. J Biol Chem 1995;270:4979-82.
59. Jaffe ES, Harris NL, Stein H, Wardiman JW. WHO classification of tumours, pathology and genetics: tumours of haematopoietic and lymphoid tissues. Lyon (France): IARC Press; 2001.
60. Kluger HM, Dolled-Filhart M, Rodov S, Kacinski BM, Camp RL, Rimm DL. Macrophage colony-stimulating factor-1 receptor expression is associated with poor outcome in breast cancer by large cohort tissue microarray analysis. Clin Cancer Res 2004;10:173-7.